J 2017

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

PROCHAZKA, V., T. PAPAJIK, Andrea JANÍKOVÁ, D. BELADA, T. KOZAK et. al.

Základní údaje

Originální název

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

Autoři

PROCHAZKA, V., T. PAPAJIK, Andrea JANÍKOVÁ, D. BELADA, T. KOZAK, David ŠÁLEK, A. SYKOROVA, H. MOCIKOVA, V. CAMPR, J. DLOUHA, K. LANGOVA, T. FURST a M. TRNENY

Vydání

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2017, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.644

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000393891300013

Klíčová slova anglicky

Autologous transplantation; chemotherapy; follicular lymphoma; prognosis

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 12. 4. 2018 18:53, Soňa Böhmová

Anotace

V originále

Optimal frontline treatment in younger high tumor-burden risk follicular lymphoma patients remains a challenge given the reduced efficacy of standard immunochemotherapy (R-CHOP) in widespread disease and unclear role of intensive induction. The retrospective non-randomized pair-matched (1: 3) analysis compared 48 intermediate/ high Follicular Lymphoma International Prognostic Index (FLIPI) patients receiving intensive rituximab sequential chemotherapy (R-SQ) with 144 random controls (R-CHOP) matched for age, FLIPI score, and maintenance delivery. Complete response rates were 91.7% and 74.1%, respectively (p = .038). After a median followup of 8.8 (R-SQ) and 6.5 years (R-CHOP), 5-year time to treatment failure, progression-free survival, and overall survival were 80.9%, 83.2%, and 100% and 57.5%, 60.3%, and 92.1% (p = .0044; p = .0047; p = .22), respectively. Intensive treatment was accompanied by higher acute hematologic toxicity and infections, comparable non-hematologic toxicity, and incidence of secondary malignancies. Intensive induction demonstrates superior long-term disease control compared to R-CHOP, with higher acute hematologic toxicity, but without acute treatment-related mortality. Further studies are needed to define ultra-high-risk FL patients benefiting most from treatment intensity.